Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis.

International journal of oncology - 1 Dec 2022

Liu Xiaofeng, Hai Yang, Dong Jinqu, Xu Lan, Hou Wenqian, Su Jing, Ren Weiyu, Liu Dongling

Abstract excerpt

KRAS is a biomarker for non‑small cell lung cancer‑targeted therapy, but there is currently no effective KRAS‑targeting medication. Realgar is an impelling anticancer drug, however its significance in KRAS mutant lung cancer is uncertain. According to our findings, the IC50 of H23 (KRAS mutant) cells is 2.99 times lower than that of H1650 (non‑KRAS mutant) cells. Flow cytometry and the Hoechst 33258 staining...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferroptosis

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 36321791
DOI: 10.3892/ijo.2022.5447
PMCID: PMC9635866

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis.PMID 36321791Read ↗

Regulation of Ferroptosis in Lung AdenocarcinomaSemantic proximity Read ↗

Ferroptosis: Therapeutic Potential and Strategies in Non-Small Cell Lung CancerSemantic proximity Read ↗

Valtrate antagonizes malignant phenotypes of lung cancer cells by reducing SLC7A11.Semantic proximity Read ↗

Review of ferroptosis in colorectal cancer: Friends or foes?Semantic proximity Read ↗

Insights Into Ferroptosis, a Novel Target for the Therapy of CancerSemantic proximity Read ↗

Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.Semantic proximity Read ↗

Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Tenovin 3 induces apoptosis and ferroptosis in EGFR 19del non small cell lung cancer cells.Semantic proximity Read ↗

SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.Semantic proximity Read ↗

Overview of Ferroptosis and Synthetic Lethality StrategiesSemantic proximity Read ↗

Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.Semantic proximity Read ↗

Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.